Clinical pharmacokinetics of imatinib mesylate

In Vivo

Volumn 19, Issue 1, 2005, Pages 77-84

  Levêque, Dominique ^a   Maloisel, Frédéric ^b  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b HÔPITAL CIVIL   (France)

Author keywords

Imatinib mesylate; Pharmacokinetics

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CGP 74588; CLINDAMYCIN; CYCLOSPORIN; DIGOXIN; DRUG METABOLITE; ERYTHROMYCIN; HYPERICUM PERFORATUM EXTRACT; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; METHOTREXATE; MIDAZOLAM; MITOXANTRONE; NORIMATINIB; PHENOBARBITAL; RIFAMPICIN; SIMVASTATIN; TOPOTECAN; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MYOPATHY; NONHUMAN; PHARMACODYNAMICS; PHILADELPHIA 1 CHROMOSOME; REVIEW; RHABDOMYOLYSIS;

EID: 16244385619     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Savage DG and Antman KH: Imatinib mesylate. A new oral targeted therapy. New Engl J Med 346: 683-693, 2002.
2. Thambi P and Sausville EA: STI571 (imatinib mesylate): the tale of a targeted therapy. Anti-Cancer Drugs 13: 111-114, 2002.
3. Capdeville R, Buchdunger E, Zimmermann J and Matter A: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502, 2002.
4. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D and Pazdur R: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034-3038, 2002.
5. Croom KF and Perry CM: Imatinib mesylate in the treatment of gastrointestinal stromal tumors. Drugs 63: 513-522, 2003.
6. Kurzrock R, Kantarjian HM, Druker BJ and Talpaz M: Philadelphia chromosome-positive leukemia: from basic mechanisms to molecular therapeutics. Ann Intern Med 138: 819-830, 2003.
7. Deininger MWN, O'Brien SG, Ford JM and Druker BJ: Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21: 1637-1647, 2003.
8. Deininger MWN and Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55: 401-423, 2003.
9. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Drucker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
10. Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C et al: Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114: 379-388, 2004.
11. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349, 2003.
12. Bakhtiar R, Khemani L, Hayes M, Bedman T and Tse F: Quantification of the anti-leukemia drug STI571 (Gleevec®) and its metabolite CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 28: 1183-1194, 2002.
13. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M and Tse F: High-throughput quantification of the anti-leukemia drug STI571 (Gleevec®) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 768: 325-340, 2002.
14. Parise RA, Ramanathan RK, Hayes MJ and Egorin MJ: Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B 791: 39-44, 2003.
15. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L and Gupta SK: Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological fluids. J Chromatogr B 804: 431-434, 2004.
16. Le Coutre P, Kreuzer KA, Pursche S, Bonin MV, Leopold T, Baskaynak G, Dörken B, Ehninger G, Ottmann O, Jenke A, Bornhäuser M and Schleyer E: Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP 74588. Cancer Chemother Pharmacol 53: 313-323, 2004.
17. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G and D'Incalci M: α1acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9: 625-632, 2003.
18. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R and Llyod P: Absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion. J Clin Pharmacol 44: 158-162, 2004.
19. Nikolova Z, Peng B, Hubert M, Seiberling M, Keller U, Ho YY, Schran H and Capdeville R: Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 53 433-438, 2004.
20. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Llyod P and Capdeville R: Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22: 935-942, 2004.
21. Kretz O, Weiss HM, Schumacher MM and Gross G: In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 58: 212-216, 2004.
22. Gambacorti-Passerini C, Barni R, Le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F and D'Incalci M: Role of α1acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst 92: 1641-1650, 2000.
23. Benet LZ and Hoener BA: Changes in plasma protein binding have little relevance. Clin Pharmacol Ther 71: 115-121, 2002.
24. Leis JF, Stepan DE, Curtin PT, Peng B, Ford JM, Schubach SE, Fleming WH, Druker BJ and Maziarz RT: Low penetration of imatinib (STI571) into the CSF indicates the need for standard CNS prophylaxis in patients with CML lymphoid blast crisis and Philadelphia chromosome positive ALL. Blood 98: abstract 590, 2001.
25. Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F, Grünewald K, Poewe W and Gastl G: Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 117 623-625, 2002.
26. Takayama N, Sato N, O'Brien S, Ikeda Y and Okamoto SI: Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119: 106-108, 2002.
27. Eville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL and Blaney SM: Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res 10: 2525-2529, 2004.
28. Levêque D and Jehl F: P-glycoprotein and pharmacokinetics. Anticancer Res 15: 331-336, 1996.
29. Lin J and Yamazaki M: Role of P-glycoprotein in pharmacokinetics. Clinical implications. Clin Pharmacokinet 42: 59-98, 2003.
30. Hamada A, Miyano H, Watanabe H and Saito H: Interaction of imatinib mesylate with human P-glycoprotein. J Pharmacol Exp Ther 307 824-828, 2003.
31. Dai H, Marbach P, Lemaire M, Hayes M and Elmquist WF: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304: 1085-1092, 2003.
32. Ramalingam S, Lagattuta TF, Egorin MJ, Hayes MJ and Ramanathan RK: Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans. Pharmacotherapy 24: 1232-1235, 2004.
33. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, Therrien M, Zoellner U, Blaney SM and Bernstein M: Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase I study. Blood 104: 2655-2660, 2004.
34. Cypriano MS, Jenkins JJ, Pappo AS, Rao BN and Daw NC: Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer 101: 39-50, 2004.
35. Remick SC, Ramanathan RK, Mulkerin D, Doroshow JH, Takimoto CH, Grem JL, Lorusso P, Ivy SP, Murgo AJ and Egorin MJ: A phase I pharmacokinetic study of STI-571 in patients with advanced malignancies and varying degrees of renal dysfunction. Proc Am Soc Clin Oncol 22 126, 2003 (abstract).
36. Abrams PL, Egorin MJ, Ramanathan RK, Parise RA, Lagattuta TF, Hayes M, Peng B, Ivy SP, Murgo AJ and Remick SC: Intrapatient consistency of imatinib pharmacokinetics in patients with advanced cancers. Proc Am Soc Clin Oncol 23: 147, 2004 (abstract).
37. Ramanathan RK, Remick SC, Mulkerin D, Takimoto C, Doroshow JH, Hamilton A, Lorusso P, Ivy P, Murgo A and Peng B: A phase I pharmacokinetic study of STI-571 in patients with advanced malignancies and varying degrees of liver dysfunction. Proc Am Soc Clin Oncol 22 126, 2003 (abstract).
38. Gurney H, Wong M, Rivory L, Wilcken N, Hoskins J, Collins M, Dellaforce SE, Lynch K and Schran H: Imatinib elimination: characterization by in vivo testing of phenotype and genotype. Proc Am Soc Clin Oncol 22: 193, 2003 (abstract).
39. Pauli-Magnus C and Kroetz DL: Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 21: 904-913, 2004.
40. Reckmann AH, Fisher T, Peng B, Hayes M, Mehring G, Reese S, Resta D, Ben-Am M, Gschaidmeier H, Huber C and Capdeville R: Effect of food on STI571 Glivec pharmacokinetics and bioavailability. Proc Am Soc Clin Oncol 20: 307a, 2001 (abstract).
41. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E and Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN38 in vitro. Cancer Res 64: 2333-2337, 2004.
42. Burger H, van Tol H, Boersma AWM, Brok M, Wiemer EAC, Stoter G and Nooter K: Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940-2942, 2004.
43. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R and Seiberling M: Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54: 290-294, 2004.
44. Schuetz E and Strom S: Promiscuous regulator of xenobiotic removal. Nat Med 7: 536-537, 2001.
45. Xie W, Uppal H, Saini SPS, Mu Y, Little JM, Radominska-Pandya A and Zemaitis MA: Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism. Drug Discov Today 9: 442-449, 2004.
46. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U and Seiberling M: Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53: 102-106, 2004.
47. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS and Jusko WJ: Induction of imatinib metabolism by hypericum perforatum. Blood 104: 1229-1230, 2004.
48. Frye RF, Fitzgerald SM, Lagattuta F, Hruska MW and Egorin MJ: Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76: 323-329, 2004.
49. O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C, Mehring G, Milosavljev S, Huber C, Capdeville R and Fischer T: Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89: 1855-1859, 2003.
50. Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH and Prueksaritanont T: Interactions of human P-glycoprotein with simvastatin, simvastatin acid and atorvastatin. Pharm Res 21: 1686-1691, 2004.